

## ACKNOWLEDGEMENT

First and above all, I praise God, the almighty for providing me this opportunity and granting me the capability to proceed successfully not only in this work, but indeed, throughout my life. "I can do everything through him who gives me strength." (Philippians 4: 13). This thesis appears in its current form due to the assistance and guidance of several people. I would therefore like to offer my sincere thanks to all of them.

I would like to deeply thank Prof. Dr. Sawsan El-Masry, professor of Pharmacognosy, Faculty of Pharmacy, Alexandria University, for suggesting the point of the thesis, her kind supervision, continuous support, her patience, motivation, enthusiasm, and her immense knowledge. I am very grateful for her careful instructions and constructive criticism whenever I was mistaken, whether throughout the Experimental or the writing experience.

I would like to express my deepest gratitude to Prof. Dr. Masouda El-Sayed Amer, Professor of Pharmacognosy, Faculty of Pharmacy, Alexandria University, for her kind and encouraging supervision. I would really like to thank her for her motivational support to keep me moving forward and for handling all the encountered obstacles over the past years.

I would like to express my deep gratitude to Prof. Dr. Mohamed Ahmed El-Said Etman, Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Prof. Dr. Fathy Kandeel El-Fiky Professor of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Dr. Khaled Meslhy, Departement of Pharmacognosy, faculty of pharmacy, Cairo Univesity for supplying reference mateials. I owe a great deal of appreciation and gratitude to Dr. Mohammed Bahey-El-Din, Department of Microbiology, Faculty of Pharmacy, Alexandria University, for carrying out the microbial count analyses. Special thanks to Eng. Emil Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic, for carrying out terpene trilactones and ginkgolic acid analyses.

I would like to express the deepest appreciation to my wonderful colleagues and friends specially Simona Shawky. Really thank you all for your help, support and for providing a stimulating and fun filled environment. I would also like to extend my thanks to the technicians of the central laboratory especially Nesma Magdy, Mohamed Ebrahim, and Marah Mostafa for their excellent technical assistance in the lab.

I would like express appreciation to my little angle Angela and my beloved husband Peter. No words to say how much I appreciate you and how much I thank you for everything you have done to me. Without your love, assistance, and encouragement, I would not have finished this thesis. I am grateful to have a husband like you. Really thanks for being understanding. At the end I would like to thank my parents and my brother for their unconditional support, throughout my degree. Words cannot express how grateful I am to all of them. I will do my best to make you all proud. A special thanks to my mother-in law, father-in-law, for all their help and encouragement. Your prayer for me was what sustained me thus far. I love you.

## TABLE OF CONTENTS

TABLE OF CONTENTS.....	II
LIST OF ABBREVIATIONS.....	IV
LIST OF TABLES.....	V
LIST OF FIGURES.....	VI
INTRODUCTION.....	1
1. Historical background on the ancient use of herbal products as medicines.....	1
1.1. The use of botanicals as medicine.....	1
1.2. The move to synthetic drugs in 19 <sup>th</sup> century.....	2
1.3. “The Back to Nature” move for medication with botanical products.....	2
2. <i>Ginkgo biloba</i> L. as botanical dietary supplements or medicines.....	3
2.1. Historical use of <i>Ginkgo biloba</i> L.....	3
2.2. <i>Ginkgo biloba</i> L. tree.....	3
2.3. <i>Ginkgo biloba</i> L. extract.....	4
2.4. Constituents responsible for <i>Ginkgo biloba</i> L. activity.....	5
2.4.1. <i>Ginkgo</i> flavonoids.....	5
2.4.2. <i>Ginkgo</i> terpenoids.....	7
2.5. Negative markers of <i>Ginkgo biloba</i> L.....	9
2.5.1. Ginkgolic acids.....	9
2.5.2. Ginkgotoxin.....	10
2.6. Medicinal importance of <i>Ginkgo biloba</i> L.....	10
2.7. <i>Ginkgo biloba</i> L. drug interaction, side effects, and dosage.....	10
2.8. Content variation of <i>Ginkgo biloba</i> L. constituents in relation to age, gender, and collection time of the leaves.....	11
2.9. <i>Ginkgo biloba</i> L. nowadays.....	12
3. Regulation of dietary supplements internationally.....	13
4. Methods used for the assessment of botanicals.....	14
4.1. Compendial methods.....	15
4.1.1. USP monographs.....	15
4.1.2. WHO monographs.....	15
4.1.3. Commission E monographs.....	16

---

---

4.1.4. ESCOP monographs .....	16
4.1.5. Pharmacopoeia of the People's Republic of China Monographs.....	16
4.2. Pitfall of compendial monographs for quality assessment of <i>Ginkgo biloba</i> L. extract.....	17
4.3. Chromatographic and tandem methods.....	20
4.4. Available analytical methods used for the quality assessment of <i>Ginkgo biloba</i> L. dietary supplements.....	21
AIM OF THE WORK.....	23
MATERIALS, METHODS, & EQUIPMENT .....	24
RESULTS .....	31
DISCUSSION.....	47
SUMMARY AND CONCLUSION .....	53
REFERENCES .....	57

---

---

## LIST OF ABBREVIATIONS

BP	British Pharmacopoeia
USP	United States Pharmacopoeia
USP-NF	United States Pharmacopoeia-National Formulary
DSC	Dietary Supplement Compendium
Ph. Eur.	European Pharmacopoeia
DSHEA	Dietary Supplement Health and Education Act
EGb 761	<i>Ginkgo biloba</i> L. Extract 761
FDA	Food and Drug Administration
cGMP	Current Good Manufacturing Practices
ESCOB	European Scientific Cooperation on Phytotherapy
SFDA	State Food and Drug Administration of China
EDA	Egyptian Drug Authority
CAPA	Central Administration of Pharmaceutical Affairs
NODCAR	National Organization for Drug Control and Research
NORCB	National Organization for Research and Control of Biologicals
WHO	World Health Organization
TLC	Thin Layer Chromatography
HPLC	High Performance Liquid Chromatography
HPTLC	High Performance Thin Layer Chromatography
GC	Gas Chromatography
Q	Quercetin
K	Kaempferol
I	Isorhamnetin
CNS	Central Nervous System
BBB	Blood Brain Barrier
PDA	Photo Diode Array

---

---

## LIST OF TABLES

<b>Table</b>	<b>Page</b>
Table 1. Different classes of compounds present in EGb 761.....	5
Table 2. <i>Ginkgo biloba</i> L. documented drug interactions. ....	11
Table 3. <i>Ginkgo biloba</i> L. containing products used for the quality assessments. ....	25
Table 4. Products containing <i>Ginkgo biloba</i> L. extracts and used for the USP microbial enumeration tests. ....	26
Table 5. Results of HPLC analyses of flavonol glycosides content and the ratio of (Q/K/I) of two commercial extracts (1&2) and 10 products (A-J) containing <i>Ginkgo biloba</i> according to USP .....	31
Table 6. Results of HPLC analyses of 10 products containing <i>Ginkgo biloba</i> L. extracts for the quercetin content before and after hydrolysis. ....	32
Table 7. Results of HPLC analyses of 10 products containing <i>Ginkgo biloba</i> L. extracts for the rutin and quercetrin glycosides content before hydrolysis.....	33
Table 8. Ratio of the free aglycones (quercetin and kaempferol) to the intact glycosides quercetrin in the examined <i>Ginkgo biloba</i> L. containing products and its indication. ....	34
Table 9. Percentage of bilobalide, total ginkgolides and total terpene trilactones in the <i>Ginkgo biloba</i> L. containing products assayed by HPLC-MS.....	35
Table 10. Limits of ginkgolic acids (GAs) found in the examined products assayed by HPLC-MS. ....	35
Table 11. Results of analyses of five products for the rutin and quercetrin contents at zero time and after 6 months. ....	46

---

---

## LIST OF FIGURES

<b>Figure</b>	<b>Page</b>
Figure 1. The Ebers papyrus. ....	1
Figure 2. <i>Ginkgo biloba</i> L. tree. ....	3
Figure 3. <i>Ginkgo biloba</i> L. leaves. ....	4
Figure 4. Structures of selected flavonols and flavonol glycosides in <i>Ginkgo biloba</i> L. ....	6
Figure 5. Two major flavonol-acyl-glycosides of <i>Ginkgo biloba</i> L. ....	7
Figure 6. Structures of ginkgolides and bilobalide in <i>Ginkgo biloba</i> L. ....	8
Figure 7. Ginkgolic acids structures. ....	9
Figure 8. Comparison of the total flavonol glycosides in the <i>Ginkgo biloba</i> L. leaves collected from different ages and genders. ....	12
Figure 9. Comparison of the total terpene trilactones in the <i>Ginkgo biloba</i> L. leaves collected from different ages and genders. ....	12
Figure 10. Work-up procedure for HPLC determination of flavonoid aglycones. ....	19
Figure 11. Calculation of <i>Ginkgo</i> flavonol glycosides content. ....	20
Figure 12. HPTLC chromatograms of unhydrolyzed extracts from preparations (1-8), <i>Ginkgo biloba</i> L. extracts (9-11) and standard rutin (12) in UV 254 nm. ....	36
Figure 13. HPTLC chromatograms of unhydrolyzed extracts from preparations (1-8), <i>Ginkgo biloba</i> L. extracts (9-11) and standard rutin (12) using ferric chloride reagent. ....	36

---

---

Figure 14. HPLC fingerprint of Standards used (rutin (R), quercetrin (Qr), quercetin (Q), and kaempferol (K)).....	37
Figure 15. HPLC fingerprints of USP standardized <i>Ginkgo biloba</i> L. extract and two <i>Ginkgo biloba</i> L. extracts obtained from different manufacturers of dietary supplements in Egypt (1 and 2) before and after hydrolysis. ....	38
Figure 16. HPLC fingerprints of products A and B before and after hydrolysis.....	39
Figure 17. HPLC fingerprints of products C, D, E, and F before and after hydrolysis. ....	40
Figure 18. HPLC fingerprints of products G, G*, H, I, and J before and after hydrolysis..	41
Figure 19. Overlay HPLC fingerprints of product A (green), product B (olive green), and <i>Ginkgo biloba</i> L. standardized extract (blue). ....	42
Figure 20. Overlay HPLC fingerprints of product C (Navy), product D (purple), product E (green), and <i>Ginkgo biloba</i> L. extract (blue). ....	43
Figure 21. Overlay HPLC fingerprints of product G (black), product I (Navy), and <i>Ginkgo biloba</i> L. extract (blue). ....	43
Figure 22. Shows HPLC fingerprints results of five products containing <i>Ginkgo biloba</i> L. at zero time and after 6 months.....	45



